Publications
188
Citations
2,708
Est. group size
~18
Recurring co-author estimate
Active years
18
Publishing since 2009
Debasish Sundi's research focuses on bladder and urinary tract cancers, particularly non-muscle-invasive bladder cancer (early-stage cancer that has not spread into deeper bladder tissue) and urothelial carcinoma. Work spans clinical trials of intravesical (bladder-instilled) therapies like BCG and gemcitabine, biomarker and genomic profiling tools for cancer detection and monitoring using urine samples, and laboratory models for testing drug responses. This research aims to improve diagnosis, risk prediction, and treatment selection for patients with bladder and related urologic cancers.
Publication output was modest and variable from 2017-2022, then increased sharply starting in 2023, suggesting a growing and currently active research program.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- The GAIN trial: Gemcitabine alternating with intravesical BCG randomized against BCG alone for patients with recurrent “BCG-exposed” high-grade non-muscle invasive bladder cancer (NMIBC) (ALLIANCE A032303).
Journal of Clinical Oncology · 2026
- Editorial Comment
The Journal of Urology · 2026
- Abstract PR005: Conditional Reprogramming Enables Rapid Establishment of Patient-Derived Neuroendocrine Tumor Models for Functional Precision Oncology
Cancer Research · 2026
- A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non–muscle-invasive Bladder Cancer
European Urology · 2025
- Conditional Reprogramming: A Living Biomarker and Phenotypic Screening Drug Platform for Urological Cancer
2025
- Editorial Comment
The Journal of Urology · 2025
- Chronic Epididymitis Secondary to <i>Mycobacterium tuberculosis</i> Complex After Intravesical Bacillus Calmette-Guérin Therapy for Bladder Cancer
Annals of Internal Medicine Clinical Cases · 2025
- Supplementary Figure 2 from Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction
2025
- Supplementary Tables 1-8 from Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction
2025
- Supplementary Figure 1 from Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction
2025
- Transcriptome- and proteome-wide association studies identify genes associated with renal cell carcinoma
The American Journal of Human Genetics · 2024
- Melanoma Antigen Family A (MAGE A) as Promising Biomarkers and Therapeutic Targets in Bladder Cancer
Cancers · 2024
- Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder Cancer
Bladder Cancer · 2024
- MARKER LESION STUDY OF ORAL ERDAFITINIB IN PATIENTS WITH INTERMEDIATE-RISK NON-MUSCLE–INVASIVE BLADDER CANCER WITH FGFR3/2 ALTERATIONS IN THOR-2: UPDATED COHORT 3 RESULTS
Urologic Oncology Seminars and Original Investigations · 2024
- Editorial Comment
The Journal of Urology · 2024
- The Journal of Urology×28
- Journal of Clinical Oncology×15
- Urologic Oncology Seminars and Original Investigations×7
- Cancers×5
- European Urology×4
- Ahmad Shabsigh
Medicine · The Ohio State University
- Michael Gong
Medicine · The Ohio State University
- Michael O. Koch
Medicine · Indiana University
- Debra L. Zynger
Medicine · The Ohio State University
- Shawn Dason
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile